CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Ibrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02195869
NCT02195869Phase 2Completed
CompareCT.gov

A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Pharmacyclics LLC.·interventional·Posted Jul 21, 2014·Updated Jul 11, 2019

In Brief

A Phase 2 clinical trial evaluating Ibrutinib for Graft Versus Host Disease. Completed, enrolled 45 participants across 10 sites.

Detailed Summary

The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 21, 2014
Enrollment StartJul 14, 2014
Primary CompletionSep 15, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.9 years ago

Interventions

Ibrutinibdrug